A venture capitalist made some waves early in the J.P. Morgan Healthcare Conference when he announced his new company’s mission is to make medicines less expensive. After all, two of his previous investments have fueled drug makers using genetics to treat cancer — the kind of approach that has produced remarkable outcomes but also driven up the price of drugs.

Alexis Borisy, known for co-founding Foundation Medicine and Blueprint Medicines and wearing felt fedoras, seeks to bring down prices at his new company, called EQRx. The plan is to make “equivalars,” blockbuster look-alikes that have their own intellectual property but cost far less. Borisy talked about EQRx and its chances with STAT earlier this week at JPM. 

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy